Delafloxacin may provide a feasible alternative antibiotic monotherapy option for treating patients with community-acquired bacterial pneumonia (CABP) who have renal impairment in both inpatient and outpatient settings.
All articles by Natasha Dyal
Latest News Your top articles for FridayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses